About Us | Contact Us |        

Outcomes in NSCLC: A Focus on Quality Improvement - Part 1

Outcomes in NSCLC: A Focus on Quality Improvement
1.25 AMA PRA Category 1 Credit(s)
Launch Date:
April 27, 2017
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Oncologists; oncology nurse practitioners; and physician assistants

Relevant Terms:

Non-small cell lung cancer; quality improvement; targeted therapy; molecular testing

Thomas E. Stinchcombe, MD

Thomas E. Stinchcombe, MD
Medical Instructor
Division of Medical Oncology
Department of Medicine
Duke Cancer Institute 
Durham, NC

Thomas E. Stinchcombe, MD, completed medical school at the University of Virginia, his internal medicine residency at the University of Michigan, and his hematology and oncology fellowship at the University of North Carolina.
Dr Stinchcombe’s clinical interest is in thoracic malignancies, and his research focus is clinical trials for non-small cell and small cell lung cancer. He is a member of Duke Cancer Institute and the Thoracic Oncology Program at Duke University, Durham, NC.

Srikanth Reddy, MD

Srikanth Reddy, MD
Physician, Epic Care
Castro Valley, CA
Physician, Epic Care
San Leandro, CA

Dr Reddy practices Hematology and Medical Oncology at Epic Care's Castro Valley and San Leandro Care Centers. He also has affiliations with/privileges at Eden Medical Center, Castro Valley Campus, Castro Valley, CA; Eden Medical Center, San Leandro Campus, San Leandro, CA; St Rose Hospital, Hayward, CA; and Stanford Health Care, ValleyCare Medical Center, Pleasanton, CA.
Dr Reddy was born in Brooklyn, New York, and grew up in India. He graduated with a Bachelor of Science in Chemistry at the University of California, Berkeley, and obtained his Doctor of Medicine degree from Albany Medical College in Albany, New York. Dr Reddy completed an internship, residency, and fellowship at the University of California, Irvine. During his tenure, he received departmental awards for both service and promoting the education mission of UCI Medical Center. He then served as a hospitalist at Mission Hospital in Mission Viejo, California, for one year before joining Epic Care.
Dr Reddy is a member of The American Society of Clinical Oncology (ASCO), the Alameda-Contra Costa Medical Association (ACCMA), the Association of Northern California Oncologists (ANCO), and the American Society of Hematology (ASH). His areas of special interest include lymphomas and benign hematology.

Amit Singh Tibb, MD, FCCP

Amit Singh Tibb, MD, FCCP
Chief Quality Officer, Valley Medical Group
Director of Palliative Medicine, The Valley Hospital
Ridgewood, NJ
Clinical Assistant Professor of Medicine
Albert Einstein College of Medicine
Bronx, NY

Dr Tibb currently serves as Chief Quality Officer of the Valley Medical Group, in addition to being the Medical Director of Palliative Care at The Valley Hospital. Dr Tibb is Board certified in Internal Medicine, Pulmonary Diseases, Critical Care, Neurocritical Care and Palliative & Hospice Medicine. He retains faculty position as Clinical Assistant Professor of Medicine at Albert Einstein College of Medicine.

Dr Tibb graduated from Lokmanya Tilak Municipal Medical College, at the University of Mumbai, and completed his residency and fellowship at Albert Einstein College of Medicine, Bronx, New York. In addition, Dr Tibb completed a fellowship in Medical Simulation and held faculty position at the Institute of Medical Simulation and Learning (IMSAL). He also completed a fellowship in Clinical Quality and Patient Safety, and his work has been recognized both locally and nationally with several awards for Quality Improvement. 

In 2012-13 and 2013-14, Dr Tibb received the 'GAGE' award from America's essential hospitals for "Palliative Care Integration in the ICU" & "CAUTI reduction – Journey towards ZERO" respectively.  At Valley Medical Group, Dr Tibb is involved with Population Health and is instrumental in using Quality Metrics to drive physician compensation. Dr Tibb has served as faculty for numerous medical societies, including several Critical Care Ultrasound courses over the last 7 years, and has given grand rounds on integration of Ultrasound in the Intensive Care Unit, both nationally and internationally. His work in Quality Improvement has been recognized nationally with several awards and Dr Tibb has several peer-reviewed publications. His exemplary work as an educator has been recognized in the form of "Best Educator" award for 3 consecutive years from 2011-2014. Dr Tibb is a standing Fellow of the American College of Chest Physicians. 
1. Utilize a comprehensive understanding of histopathologic and molecular underpinnings of non-small cell lung cancer (NSCLC) and efficacy and safety data for agents used to treat NSCLC to select the most appropriate personalized therapies
2. Implement the most effective treatment strategies for patients with NSCLC using current evidence-based guidelines for sequencing, combination chemotherapy, and targeted therapy
3. Engage patients with NSCLC in their healthcare by implementing effective shared decision-making strategies
4. Describe the use of quality measures and quality improvement processes in improving the outcomes of patients with NSCLC

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
  • Thomas E. Stinchcombe, MD, has affiliations with ARIAD Pharmaceuticals, Inc., AbbVie, and Celgene (Consulting Fees).
  • Amit Singh Tibb, MD, FCCP, has no affiliations with commercial interests to disclose.
  • Srikanth Reddy, MD, has no affiliations with commercial interests to disclose.
RMEI Medical Education, LLC
  • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
  • Joshua Kilbridge has no affiliations with commercial interests to disclose.
  • Nora Hartley has no affiliations with commercial interests to disclose.
Postgraduate Institute for Medicine
The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Estimated time to complete: 1.25 hour
Media: Internet
There is no fee for this educational activity.

This activity is supported by an independent medical educational grant from Genentech.
This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and physician assistants are entitled to receive up to 1.25 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:
  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.
Physicians, nurse practitioners, and physician assistants who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.